These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1205 related articles for article (PubMed ID: 18093827)
1. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M; Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827 [TBL] [Abstract][Full Text] [Related]
2. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer. Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781 [TBL] [Abstract][Full Text] [Related]
3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD; Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575 [TBL] [Abstract][Full Text] [Related]
5. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F; Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M; Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363 [TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus]. Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287 [TBL] [Abstract][Full Text] [Related]
8. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Moehler M; Galle PR; Gockel I; Junginger T; Schmidberger H Best Pract Res Clin Gastroenterol; 2007; 21(6):965-81. PubMed ID: 18070698 [TBL] [Abstract][Full Text] [Related]
9. Localized adenocarcinoma of the esophagogastric junction--is there a standard of care? Power DG; Reynolds JV Cancer Treat Rev; 2010 Aug; 36(5):400-9. PubMed ID: 20117883 [TBL] [Abstract][Full Text] [Related]
10. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer. Veuillez V; Rougier P; Seitz JF Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697 [TBL] [Abstract][Full Text] [Related]
12. Role of neoadjuvant therapy for esophageal adenocarcinoma. Ku GY; Ilson DH Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742 [TBL] [Abstract][Full Text] [Related]
13. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079 [TBL] [Abstract][Full Text] [Related]
14. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of resected gastric cancer is necessary. Carrato A; Gallego-Plazas J; Guillen-Ponce C Semin Oncol; 2005 Dec; 32(6 Suppl 9):S105-8. PubMed ID: 16399445 [TBL] [Abstract][Full Text] [Related]